GENE ONLINE|News &
Opinion
Blog

2021-10-14| In-DepthSpecial

Anti-cancer Agent Derived From Himalayan Caterpillar Fungus Shines in Early Trials

by Manju Bhaskar
Share To
Cancer continues to be one of the deadliest diseases on the planet. According to the International Agency for Research on Cancer, in 2018, there were 18.1 million new diagnoses around the world, and about 9.5 million reported deaths.

Last week, NuCana, a UK-based clinical-stage biopharma, announced promising results in an early clinical trial for its potent anti-cancer molecule NUC-7738 derived from Himalayan Caterpillar Fungus.

NUC-7738 is synthesized by researchers at the University of Oxford in partnership with NuCana. Researchers reported encouraging signals of anti-tumor activity and prolonged disease stabilization in patients participating in the ongoing Phase 1 trial, which began in 2019.

NuCana harnesses the power of ProTide technology (phosphoramidate chemistry) to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms of existing nucleoside analogs. Hugh S. Griffith, Founder and CEO of believes “NuCana is striving to significantly improve outcomes for patients by transforming chemotherapy and pioneering a new era in oncology.”

GO Prime with only $1.49 now

LATEST
Blueprint Medicines Gathers Up To $1.25 Billion in Loans and Investments for Research and Development
2022-07-01
FDA Halts Sanofi’s $3.7B Multiple Sclerosis Investment
2022-07-01
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
Bon Natural Life Limited Announces Change to Board Composition
2022-06-30
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
US Bio-Entrepreneur Program Launches in the UK
2022-06-30
ReCode Therapeutics’ Secures an Extra $120 Million To Support Its Drug Delivery Platform
2022-06-30
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top